

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



SinoMab BioScience Limited

中國抗體製藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 3681)

NOTICE OF EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the “**EGM**”) of SinoMab BioScience Limited (the “**Company**”) will be held at Room 3, 14/F, Fairmont House, 8 Cotton Tree Drive, Central, Hong Kong on Monday, 7 September 2026 at 10:00 a.m. for the purpose of considering and, if thought fit, passing, with or without amendments, the following ordinary resolution. Capitalised terms used in this notice shall have the same meanings as those defined in the circular of the Company dated 21 August 2026 (the “**Circular**”) of which this notice forms part, unless the context otherwise requires:

ORDINARY RESOLUTION

“**THAT:**

- (a) the sale and purchase agreement dated 6 July 2026 entered into between MediNexus Pharma (Suzhou) Limited (杏聯藥業(蘇州)有限公司), a wholly-owned subsidiary of the Company, as vendor, Suzhou Yigong Pinyuan Biopharmaceutical Co., Ltd.* (蘇州宜工品源生物醫藥有限公司) as purchaser and MediLink Therapeutics (Suzhou) Co., Ltd. (蘇州宜聯生物醫藥有限公司) as guarantor (the “**Sale and Purchase Agreement**”) (copy of which has been produced at the EGM and marked “**A**” and initialled by the chairman of the EGM for the purpose of identification) in relation to the disposal (the “**Disposal**”) of the state-owned construction land use right of the land parcel located to the east of Jingu Road and north of Jiangyun Road, Suzhou Industrial Park, together with the factory premises situated thereon at No. 59 Jinhai Road, Suzhou Industrial Park, the ancillary facilities, related fittings and fixtures, and all assets, rights and interests appurtenant or relating thereto for a total consideration of RMB280,000,000, and the transactions contemplated thereunder be and are hereby approved, confirmed and ratified; and

- (b) any one Director be and is hereby authorised to do all such acts and things, and to sign, execute, deliver and approve all such documents, instruments and agreements (under hand or, where required, under the common seal of the Company together with another Director or such other person authorised by the board of Directors) as he/she may in his/her absolute discretion consider necessary, appropriate or desirable to implement and give effect to the Disposal and the transactions contemplated thereunder.”

By Order of the Board
SinoMab BioScience Limited
Dr. Shui On LEUNG
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 21 August 2026

Notes:

1. All resolutions at the meeting will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). The results of the poll will be published on the websites of Hong Kong Exchanges and Clearing Limited and the Company in accordance with the Listing Rules.
2. Any shareholder of the Company entitled to attend, speak and vote at the meeting is entitled to appoint a proxy or if he is the holder of two or more shares, more than one proxy to attend, speak and on a poll, vote instead of him. A proxy need not be a shareholder of the Company. If more than one proxy is appointed, the number of shares in respect of which each such proxy so appointed must be specified in the relevant form of proxy. Every shareholder present in person or by proxy shall be entitled to one vote for each share held by him.
3. In order to be valid, the form of proxy and any authority, if any, under which it is signed, or a copy of such power or authority, must be deposited at the Company’s share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong not less than 48 hours (excluding any part of a day that is a public holiday) before the time appointed for the meeting (i.e. not later than 10:00 a.m. on Friday, 4 September 2026) or the adjourned meeting (as the case may be). Completion and return of the form of proxy shall not preclude a shareholder of the Company from attending and voting in person at the meeting or poll concerned and, in such event, the instrument appointing a proxy shall be deemed to be revoked.
4. The record date for determining the entitlement of shareholders to attend, speak and vote at the meeting is Monday, 7 September 2026. The register of members of the Company will be closed from Wednesday, 2 September 2026 to Monday, 7 September 2026, both dates inclusive, during which period no transfer of shares will be registered. In order to be eligible to attend, speak and vote at the EGM, unregistered holders of shares of the Company shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company’s share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong for registration not later than 4:30 p.m. on Tuesday, 1 September 2026.
5. If a tropical cyclone warning signal number 8 or above is hoisted, or “extreme conditions” caused by super typhoons or a black rainstorm warning is/are in force at or at any time after 6:00 a.m. on Monday, 7 September 2026, the EGM will not be held on Monday, 7 September 2026 but will be postponed to a later date and if postponed, the Company will as soon as practicable post an announcement on the websites of Hong Kong Exchanges and Clearing Limited and the Company. Shareholders may contact Customer Service Hotline of Computershare Hong Kong Investor Services Limited at (852) 2862 8555 from 9:00 a.m. to 5:00 p.m., Monday to Friday (excluding public holidays) for any enquiry regarding the aforesaid arrangement.

6. References to time and dates in this notice are to Hong Kong time and dates.

As at the date of this notice, the executive director of the Company is Dr. Shui On LEUNG, the non-executive directors of the Company are Ms. Lei XUE, Ms. Xiaosu WANG and Dr. Jianmin ZHANG, and the independent non-executive directors of the Company are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE, Ms. Chi Sau Giselle LEE and Mr. Nan SHEN.

* *For identification purposes only*